In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price target of $30.00. The company’s shares closed yesterday at $7.99.
Tsao covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Revance Therapeutics, and Daré Bioscience. According to TipRanks, Tsao has an average return of 1.0% and a 37.56% success rate on recommended stocks.
Coherus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $26.67, which is a 233.79% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $28.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $19.32 and a one-year low of $5.60. Currently, Coherus Biosciences has an average volume of 1.03M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Read More on CHRS: